Abstract
A double-blind placebo trial of fluphenazine decanoate, a long-acting phenothiazine, was carried out to determine its value in maintenance therapy of chronic schizophrenic outpatients already established on the drug for a minimum period of eight weeks. In low doses it was significantly more effective than placebo in preventing relapse and admission to hospital. Relapse was accompanied by a resurgence of specifically schizophrenic symptoms and by an increase in abnormalities described by the relatives. There was no difference between the experimental and control groups in the treatment required for depression. The group on active medication required more treatment for Parkinsonism, but this difference did not reach statistical significance.
In the context of a well-run special clinic for outpatient follow-up of chronic schizophrenic patients these results confirm the usefulness of long-acting fluphenazine. By inference, the benefit of this treatment highlights the need for adequate community services to deal with the residual chronic disabilities which are characteristic of these patients.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bankier R. G., Pettit D. E., Bergen B. A comparative study of fluphenazine enanthate and trifluoperazine in chronic schizophrenic patients. Dis Nerv Syst. 1968 Jan;29(1):56–60. [PubMed] [Google Scholar]
- Birley J. L., Brown G. W. Crises and life changes preceding the onset or relapse of acute schizophrenia: clinical aspects. Br J Psychiatry. 1970 Mar;116(532):327–333. doi: 10.1192/bjp.116.532.327. [DOI] [PubMed] [Google Scholar]
- Blackwell B., Shepherd M. Prophylactic lithium: another therapeutic myth? An examination of the evidence to date. Lancet. 1968 May 4;1(7549):968–971. doi: 10.1016/s0140-6736(68)90917-3. [DOI] [PubMed] [Google Scholar]
- Bucci L., Fuchs M., Simeon J., Fink M. Depot fluphenazine in the treatment of psychosis in a community mental health clinic. Dis Nerv Syst. 1970 Sep;31(Suppl):28–31. [PubMed] [Google Scholar]
- Denham J., Adamson L. The contribution of fluphenazine enanthate and decanoate in the prevention of readmission of schizophrenic patients. Acta Psychiatr Scand. 1971;47(4):420–430. doi: 10.1111/j.1600-0447.1971.tb03699.x. [DOI] [PubMed] [Google Scholar]
- Goldberg S. C., Mattsson N., Cole J. O., Klerman G. L. Prediction of improvement in schizophrenia under four phenothiazines. Arch Gen Psychiatry. 1967 Jan;16(1):107–117. doi: 10.1001/archpsyc.1967.01730190109015. [DOI] [PubMed] [Google Scholar]
- Haider I. A controlled trial of fluphenazine enanthate in hospitalized chronic schizophrenics. Br J Psychiatry. 1968 Jul;114(512):837–841. doi: 10.1192/bjp.114.512.837. [DOI] [PubMed] [Google Scholar]
- Johnson D. A., Freeman H. Long-acting tranquillizers. Practitioner. 1972 Mar;208(245):395–400. [PubMed] [Google Scholar]
- Kurland A. A., Richardson J. H. A comparative study of two long acting phenothiazine preparations, fluphenazine-enanthate and fluphenazine-decanoate. Psychopharmacologia. 1966;9(4):320–327. doi: 10.1007/BF00408331. [DOI] [PubMed] [Google Scholar]
- Leff J. P., Wing J. K. Trial of maintenance therapy in schizophrenia. Br Med J. 1971 Sep 11;3(5775):599–604. doi: 10.1136/bmj.3.5775.599. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Oldham A. J. Community psychiatry in London. A the-year analysis. Br J Psychiatry. 1969 Apr;115(521):465–474. doi: 10.1192/bjp.115.521.465. [DOI] [PubMed] [Google Scholar]
- RAVARIS C. L., WEAVER L. A., BROOKS G. W. A CONTROLLED STUDY OF FLUPHENAZINE ENANTHATE IN CHRONIC SCHIZOPHRENIC PATIENTS. Dis Nerv Syst. 1965 Jan;26:33–39. [PubMed] [Google Scholar]
- Rasmussen O. S. Fluphenazine enanthate in sesame oil, a depot preparation. Acta Psychiatr Scand. 1970;46(3):311–318. doi: 10.1111/j.1600-0447.1970.tb02121.x. [DOI] [PubMed] [Google Scholar]
- Stevens B. C. Dependence of schizophrenic patients on elderly relatives. Psychol Med. 1972 Feb;2(1):17–32. doi: 10.1017/s0033291700045578. [DOI] [PubMed] [Google Scholar]